相关实验视频

Updated: Jun 18, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

在患有慢性肝炎D和晚期慢性肝病的患者中,使用布列维的长期治疗

Ayaz Sapuk¹, Leonie Steinhoff¹, Kristin Huenninghaus¹

¹Department of Gastroenterology, Hepatology and Transplantational Medicine University Hospital Essen, and Faculty of Medicine University of Duisburg-Essen, Essen, Germany.

Canadian journal of gastroenterology & hepatology

|July 31, 2024

概括

布列维 (BLV) 在长期治疗晚期慢性肝病 (ACLD) 慢性肝炎D (CHD) 患者的疗效和安全性. 在大多数患者中,长期的BLV治疗导致显著的病毒载量减少和稳定的肝功能.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
药理学药理学是指药理学的学科.

背景情况:

慢性肝炎D (CHD) 是一种严重的肝病,长期治疗数据有限.
布列维 (BLV) 已被批准用于治疗心脏病,但在晚期需要评估其长期疗效和安全性.

研究的目的:

评估bulevirtide (BLV) 在患有晚期慢性肝病 (ACLD) 和心脏病的患者的长期疗效和安全性.
为了评估病毒学和生化反应,以及肝功能标志物,在延长的BLV治疗期间.

主要方法:

对14名患有ACLD (Baveno VI标准) 的CHD患者进行了回顾性分析,他们接受了BLV 2 mg/天治疗超过12个月.
病毒学反应 (VR) 定义为HDV-RNA或负性的≥2 log10降低;生物化学反应 (BR) 作为正常化转氨基酶.
评估了HDV-RNA水平的变化,VR,BR,Child-Pugh和MELD得分,以及肝脏不补偿的发生率.

主要成果:

平均治疗持续时间为26个月; 86%的患者患有ACLD.
在HDV-RNA水平显著降低,在24个月后达到63%的负效.
随着时间的推移,观察到高VR率 (高达100%) 和中度BR率 (高达75%);儿童普和MELD得分在86%的患者中保持稳定或改善.
只有一个肝脏衰竭病例发生,与病毒突破或其他并发症无关.

结论:

对于患有心血管疾病和晚期慢性肝病 (ACLD) 的患者来说,超过一年的布列维 (BLV) 治疗是有效和安全的.
大多数患者的肝功能保持稳定或改善,肝衰竭的发病率较低.
在这种患者群体中,BLV代表了管理长期结果的有价值的治疗选择.

更多相关视频

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...